Seelos Therapeutics Analyst Ratings
Seelos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 233.64% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 66.82% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 233.64% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 817.51% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 233.64% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 900.92% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 900.92% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 233.64% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 150.23% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 567.28% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 108.52% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 567.28% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 734.1% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 1151.15% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1067.74% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 66.82% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 233.64% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月22日 | 66.82% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023年08月15日 | 66.82% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023/06/23 | 66.82% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023/06/23 | 233.64% | 基準 | $4→$4 | 重申 | 投機性買入→投機性買入 |
| 2023年05月16日 | 66.82% | 康託·菲茨傑拉德 | $3→$2 | 維護 | 超重 |
| 2023年05月15日 | 233.64% | BTIG | $11→$4 | 維護 | 買 |
| 03/30/2023 | 817.51% | BTIG | →$11 | 維護 | 買 |
| 03/24/2023 | 233.64% | 基準 | $6→$4 | 維護 | 買 |
| 02/13/2023 | 900.92% | BTIG | $12→$12 | 維護 | 買 |
| 04/28/2022 | 900.92% | BTIG | →$12 | 維護 | 買 |
| 03/14/2022 | 233.64% | B.萊利證券 | $6→$4 | 維護 | 買 |
| 03/08/2022 | 150.23% | 康託·菲茨傑拉德 | $5→$3 | 維護 | 超重 |
| 09/27/2021 | 567.28% | 羅斯資本 | $2.5→$8 | 升級 | 中性→購買 |
| 2021/08/10 | 108.52% | 羅斯資本 | $4→$2.5 | 維護 | 中性 |
| 07/01/2021 | 567.28% | 古根海姆 | →$8 | 開始承保 | →購買 |
| 06/01/2021 | 734.1% | 康託·菲茨傑拉德 | →$10 | 開始承保 | →超重 |
| 03/30/2021 | 1151.15% | B.萊利證券 | →$15 | 開始承保 | →購買 |
| 03/12/2021 | 1067.74% | BTIG | →$14 | 開始承保 | →購買 |
| 2019年11月18日 | 66.82% | HC Wainwright公司 | $4→$2 | 維護 | 買 |
| 2019年11月14日 | - | 基準 | 開始承保 | →投機性買入 | |
| 2019年05月14日 | - | 羅斯資本 | 開始承保 | →購買 | |
| 2019年5月10日 | 233.64% | HC Wainwright公司 | →$4 | 開始承保 | →購買 |
What is the target price for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的目標價格是多少？
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $2.00 expecting SEEL to rise to within 12 months (a possible 66.82% upside). 9 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月22日報道了Seelos治療公司(納斯達克：SEEL)的最新目標價。這家分析公司將目標價定為2.00美元，預計SEEL將在12個月內上漲(可能上漲66.82%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的最新分析師評級是多少？
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Cantor Fitzgerald, and Seelos Therapeutics reiterated their overweight rating.
西洛斯治療公司(納斯達克代碼：SEEL)的最新分析師評級由坎託·菲茨傑拉德提供，西洛斯治療公司重申其增持評級。
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Seelos Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Seelos治療公司的上一次評級是在2023年8月22日提交的，所以你應該預計下一次評級將在2024年8月22日左右提供。
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
分析師對Seelos Treeutics(SEEL)的評級正確嗎？
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a reiterated with a price target of $0.00 to $2.00. The current price Seelos Therapeutics (SEEL) is trading at is $1.20, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Seelos治療公司(SEEL)評級被重申，目標價在0.00美元至2.00美元之間。Seelos治療公司(SEEL)目前的交易價格為1.20美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。